All In Biotech

Drug Trial Radar · NCT01931839

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

Last checked: Nov 19, 2026Latest source record: May 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,164 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,164

Actual

Start

Oct 2013

Primary completion

Apr 2016

Study completion Apr 2016

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Aug 29, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of long-term treatment with lumacaftor in combination with ivacaftor in people 12 years and older with Cystic Fibrosis.

Conditions

  • Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

Interventions

  • Lumacaftor Plus Ivacaftor CombinationDrug

    Fixed dose combination tablet, oral use

  • IvacaftorDrug

    Film-coated tablet, oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A Treatment Cohort: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 105 (Study 105)
  2. Part B Treatment Cohort: Number of Participants With Treatment-Emergent AEs and SAEsTime frame: Day 1 up to Week 105 (Study 105)

Locations

166 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Anchorage, Alaska

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    La Jolla, California

  • Site not named

    Loma Linda, California

  • Site not named

    Longbeach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Madera, California

  • Site not named

    Oakland, California

  • Site not named

    Palo Alto, California

  • Site not named

    Sacramento, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Hartford, Connecticut

  • Site not named

    New Haven, Connecticut

  • Site not named

    Altamonte Springs, Florida

  • Site not named

    Hollywood, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Park Ridge, Illinois

  • Site not named

    Peoria, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    Kansas City, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    South Portland, Maine

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Worcester, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    Minneapolis, Minnesota

Showing 40 of 166 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.